FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.

Authors
Chllamma, M
Cook, Natalie
Dhani, N
Giby, K
Dodd, A
Wang, L
Hedley, D
Moore, M
Knox, J
Affiliation
Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto
Issue Date
2016-09-06

Metadata
Show full item record
Abstract
FOLFIRINOX has been shown to significantly increase both overall survival (OS) and progression-free survival (PFS) in metastatic pancreas cancer. There is limited data regarding the treatment of locally advanced pancreatic cancer. We present a retrospective study of patients with both locally advanced and metastatic pancreas cancer using FOLFIRINOX as first-line therapy in our centre.
Citation
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. 2016, 115 (6):649-54 Br J Cancer
Journal
British Journal of Cancer
URI
http://hdl.handle.net/10541/619940
DOI
10.1038/bjc.2016.222
PubMed ID
27467054
Type
Article
Language
en
ISSN
1532-1827
Collections